Haemonetics Corp. Insider Michael Kelly Sells 1,400 Shares (HAE)
Haemonetics Corp. (NYSE:HAE) Insider Michael Kelly sold 1,400 shares of Haemonetics Corp. stock on the open market in a transaction dated Friday, September 13th. The stock was sold at an average price of $40.36, for a total transaction of $56,504.00. Following the completion of the transaction, the insider now directly owns 11,337 shares of the company’s stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
HAE has been the subject of a number of recent research reports. Analysts at Benchmark Co. initiated coverage on shares of Haemonetics Corp. (NYSE:HAE) in a research note to investors on Tuesday, September 10th. They set a “buy” rating and a $49.00 price target on the stock. Separately, analysts at Craig Hallum downgraded shares of Haemonetics Corp. (NYSE:HAE) from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, July 30th. Finally, analysts at Zacks reiterated an “outperform” rating on shares of Haemonetics Corp. (NYSE:HAE) in a research note to investors on Monday, July 1st. They now have a $50.00 price target on the stock.
Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $49.50.
Haemonetics Corp. (NYSE:HAE) traded up 0.40% during mid-day trading on Tuesday, hitting $40.41. 172,548 shares of the company’s stock traded hands. Haemonetics Corp. has a one year low of $37.71 and a one year high of $45.90. The stock has a 50-day moving average of $41.01 and a 200-day moving average of $41.27. The company has a market cap of $2.077 billion and a P/E ratio of 99.14.
Haemonetics Corp. (NYSE:HAE) last issued its quarterly earnings data on Monday, July 29th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by $0.01. The company had revenue of $219.50 million for the quarter, compared to the consensus estimate of $232.98 million. During the same quarter in the previous year, the company posted $0.28 earnings per share. The company’s revenue for the quarter was up 24.4% on a year-over-year basis. On average, analysts predict that Haemonetics Corp. will post $2.34 earnings per share for the current fiscal year.
Haemonetics Corporation is a healthcare company. The Company is engaged developing and manufacturing automated blood component collection devices and surgical blood salvage devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.